COMMUNIQUÉS West-GlobeNewswire

Neuralstem to Participate at Cell and Gene Therapy World

22/01/2018 - 13:00

GERMANTOWN, Md., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq: CUR ), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced Karl Johe, Ph.D, Chief [...]

Athenex Announces Encouraging Results of the First Cohort of Phase I Clinical Trial of Oraxol and CYRAMZA® (Ramucirumab) Combination Treatment in Gastric Cancer

22/01/2018 - 13:00

BUFFALO, N.Y., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX ), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]

Elysium Health, Inc. Challenge of ChromaDex Licensed Patent Denied by Patent Trial and Appeal Board (PTAB)

22/01/2018 - 12:30

IRVINE, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ: CDXC ), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that the Patent Trial and [...]

Novo Nordisk A/S - Share repurchase programme

22/01/2018 - 12:17

Bagsværd, Denmark, 22 January 2018 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]

Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients

22/01/2018 - 09:00

TOKYO and SAN DIEGO, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503 ) (President and CEO: Yoshihiko Hatanaka, “Astellas”) and Vical Incorporated (NASDAQ: VICL ) announced today that ASP0113, an [...]

Solon Eiendom ASA : Primary insider notification

22/01/2018 - 08:31

SOLON EIENDOM ASA STOCK EXCHANGE ANNOUNCEMENT Solon Eiendom ASA - Primary insider notification (Oslo, Norway, January 19, 2018) Solon Eiendom ASA Board Member Tore Aksel Voldberg (through his wholly owned company Skøien [...]

Genmab Announces Novartis’ Intention to Transition Arzerra® (ofatumumab) from Commercial Availability to Limited Availability via Compassionate Use Programs for the Treatment of CLL in Non-US Markets

22/01/2018 - 08:06

Company Announcement Novartis intends to transition the commercial availability of Arzerra to limited availability via compassionate use programs for treatment of CLL in non-US markets. Novartis will continue to market [...]

NANOBIOTIX presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at the American Society Of Clinical Oncology Gastrointestinal Annual Meeting

22/01/2018 - 08:02

NANOBIOTIX PRESENTS FIRST PROMISING DATA FROM PHASE I/II LIVER CANCERS TRIAL OF NBTXR3 AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY GASTROINTESTINAL ANNUAL MEETING Very good safety profile with no AEs and SAEs related [...]

NANOBIOTIX présente de premières données prometteuses dans l'essai de phase I/II avec NBTXR3 dans les cancers du foie à l'ASCO GI

22/01/2018 - 08:02

Nanobiotix présente de premières données prometteuses dans l'essai de phase I/II avec NBTXR3 dans les cancers du foie à l' American Society of Clinical Oncology Gastrointestinal Annual Meeting (ASCO GI) Très bon profil [...]

Immunicum AB (publ) Announces Upcoming Presentations and Attendances at Conferences in January and February

22/01/2018 - 08:00

Press Release 22 January 2018 Immunicum AB (publ) Announces Upcoming Presentations and Attendances at Conferences in January and February Immunicum AB (publ; IMMU.ST) a biopharmaceutical company advancing a novel, [...]

Sanofi to Acquire Bioverativ for $11.6 Billion

22/01/2018 - 07:10

Sanofi to Acquire Bioverativ for $11.6 Billion Expands Sanofi's presence in specialty care and strengthens leadership in rare diseases Adds leader in the growing hemophilia market and provides platform for expansion in [...]

Sanofi va acquérir Bioverativ pour 11,6 milliards de dollars

22/01/2018 - 07:10

Sanofi va acquérir Bioverativ pour 11,6 milliards de dollars Extension de la présence de Sanofi dans la médecine de spécialités et renforcement du leadership de Sanofi dans les maladies rares Acquisition d'un leader [...]

Sanofi to Acquire Bioverativ for $11.6 Billion

22/01/2018 - 07:04

Sanofi to Acquire Bioverativ for $11.6 Billion Expands Sanofi's presence in specialty care and strengthens leadership in rare diseases Adds leader in the growing hemophilia market and provides platform for expansion in [...]

Sanofi va acquérir Bioverativ pour 11,6 milliards de dollars

22/01/2018 - 07:04

Sanofi va acquérir Bioverativ pour 11,6 milliards de dollars Extension de la présence de Sanofi dans la médecine de spécialités et renforcement du leadership de Sanofi dans les maladies rares Acquisition d'un leader [...]

ABLYNX ANNOUNCES WARRANTS EXERCISE AND CONVERSION OF BONDS

22/01/2018 - 07:02

REGULATED INFORMATION GHENT, Belgium, 22 January 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an [...]

Novartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering period

22/01/2018 - 07:01

Transaction expands Novartis Oncology neuroendocrine tumor (NET) treatment portfolio and adds radiopharmaceutical technology platform Lutathera® (lutetium Lu 177 dotatate), with a US PDUFA date of January 26, creates [...]

Gala Pharmaceuticals Sees 2018 as Breakthrough Year for Company

21/01/2018 - 08:30

ANAHEIM, Calif., Jan. 21, 2018 (GLOBE NEWSWIRE) -- Gala Pharmaceuticals Inc. (GPI) (OTCBB: GLPH ) today announced that it is focusing on key 2018 goals to drive success and build long-term shareholder value. Gala [...]

CBMG Accelerates Cell Therapy Manufacturing with GE Healthcare’s New Start-to-Finish Solution

20/01/2018 - 02:43

GE supports CBMG in its aim to speed up manufacturing timelines for its CAR T-cell therapy clinical trials and future commercialization First GE Healthcare FlexFactory™ for cell therapy installation in the world [...]

Zealand Pharma announces progress to Phase 3 with dasiglucagon for the treatment of congenital hyperinsulinism in first half 2018

19/01/2018 - 23:31

Company announcement - No. 4/2018 Zealand Pharma announces progress to Phase 3 with dasiglucagon for the treatment of congenital hyperinsulinism in first half 2018 Zealand receives FDA approval of its Investigational [...]